MSFT 417.14 0.9731% AAPL 229.0 -0.3438% NVDA 119.37 1.5137% GOOGL 163.38 0.989% GOOG 165.11 1.0465% AMZN 178.5 3.7067% META 521.31 0.5963% AVGO 162.82 3.7533% TSLA 214.11 3.7958% TSM 171.7 1.5075% LLY 960.02 2.1081% V 276.37 0.7473% JPM 224.8 1.1656% UNH 590.2 -0.2316% NVO 139.16 1.1926% WMT 77.23 1.0599% LVMUY 149.005 -0.3844% XOM 117.94 -0.1608% LVMHF 745.0 -0.4011% MA 483.34 0.5283%
Meridian Bioscience, Inc.
VIVO Details
Meridian Bioscience, Inc. (NASDAQ: VIVO) is a life sciences company that develops, manufactures, sells, and distributes diagnostic testing systems and kits, primarily for gastrointestinal and respiratory infectious diseases, elevated blood lead levels, and bulk antigens, antibodies, and bioresearch reagents used by other diagnostic manufacturers and researchers. Diagnostic and Life Sciences are the company's two operating segments.
Latest News:
FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
VIVO Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
VIVO's stock price has increased 6.45% in the past three months and is currently leaning towards the lower band of its 52-week range of USD 17.00 to USD 30.65. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 52.67. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 18.80.
Considering the uptick in the stock price, technical indicators, and current valuation, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the current price of USD 19.97, down 1.19%, as of January 06, 2022, 03:42 PM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Kalkine Equities LLC provides general information about companies and their securities. The information contained in the reports, including any recommendations regarding the value of or transactions in any securities, does not take into account any of your investment objectives, financial situation or needs. Kalkine Equities LLC is not registered as an investment adviser in the U.S. with either the federal or state government. Before you make a decision about whether to invest in any securities, you should take into account your own objectives, financial situation and needs and seek independent financial advice. All information in our reports represents our views as at the date of publication and may change without notice.
Kalkine Media LLC, an affiliate of Kalkine Equities LLC, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.